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Abstract
Background: Human enterovirus 71 (EV71) has emerged as a significant cause of acute encephalitis and deaths in
young children. The clinical manifestations caused by EV71 varied from mild hand, foot and mouth disease to
severe neurological complications and deaths, but its pathogenesis remains elusive. Antibody dependent
enhancement (ADE) infection has been reported in various viruses and has been shown to contribute to disease
severity.
Results: In this study, the presence of sub-neutralizing antibody was demonstrated to enhance EV71 infection in
THP-1 cells and increase the mortality of EV71 infection in a suckling mouse model. Further, a secondary infection
model was established to characterize the correlation between ADE and disease severity, and primary
asymptomatic EV71 infection was shown to increase the mortality of the secondary EV71 infection in suckling
mice.
Conclusions: Together, these in vitro and in vivo experiments strongly supported the hypothesis of ADE infection
of EV71. The present findings indicate ADE might contribute to the pathogenesis of severe EV71 infection, and
raise practical issues of vaccine development and antibody-based therapy.
Background
Hand, foot and mouth diseases (HFMD) are common
self-limiting illness in infants and young children, char-
acterized by ulcerating vesicles in the mouth and lesions
on the hands and feet. Small outbreaks of mild HFMD
have occurred periodically throughout the world for a
long time. Two closely related viruses, coxsackievirus 16
(CA16) and enterovirus 71 (EV71) have been identified
as the most frequent pathogens of HFMD, and other
enteroviruses, including CA5 and CA10, can also cause
HFMD. While since 1997, large outbreaks of HFMD
associated with severe neurological complications and a
high case-fatality rate have been reported in Malaysia
[1], Taiwan [2], Singapore [3], Japan [4] and other
Asian-Pacific areas. In mainland China, large outbreaks
of HFMD have been reported since 2008, resulting in
millions of cases and hundreds of deaths in children [5].
These severe forms of HFMD have been associated with
EV71 infection, which has emerged as an important
public health problem.
EV71 is a small, non-enveloped virus with a single
positive-stranded RNA genome size of about 7.4 kb in
length. It belongs to the family Picornaviridae,g e n u s
Enterovirus together with CA16. Its open reading
frame encodes a polyprotein, flanked by 5’ and 3’
untranslated regions (UTRs). The polyprotein can be
further processed into four capsid proteins (VP1, VP2,
VP3 and VP4) and seven nonstructural proteins (2A,
2B and 2C, 3A, 3B, 3C and 3D). The capsid protein
VP1 is variable and confers distinct antigenic proper-
ties. Based on VP1 gene sequence, EV71 can be
d i v i d e di n t og e n o t y p eA ,B ,a n dC[ 6 ] .G e n o g r o u p sB
and C can be further divided into 5 additional subge-
nogroups, designated B1-B5 and C1-C5, respectively
[4,7]. The predominant genotypes currently circulating
are C1, C4, C5 and B5, and different genotypes of
EV71 stains may co-circulate in the same areas. Addi-
tionally, recombination and positive selection contri-
bute to the antigenic diversity of EV71, and intra- or
inter-genotypic recombinant EV71 strains have been
reported in large outbreaks in different countries [8,9].
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cure and no vaccine to prevent severe EV71 infection,
due in part to the lack of understanding of viral patho-
genesis. Actually, the clinical manifestations of EV71
infections varied. Most EV71 infections are asympto-
matic or limited to mild HFMD and herpangina. How-
ever, EV71 is a highly neurotropic virus that can cause
severe neurological diseases and complication, such as
aseptic meningitis, brainstem encephalitis, acute flaccid
paralysis and neurogenic pulmonary edema, which has
been reviewed previously [10]. The pathogenesis of
severe EV71 infection remains somewhat unclear.
Radiologic and pathologic evidences indicated brain-
stem as the major target of EV71 infection [11]. Study
in mice also demonstrated that retrograde axonal
transport in neuron cells might be the major transmis-
sion route of EV71 [12]. Laboratory and clinical data
demonstrated that inflammatory and immune
responses also contribute to the pathogenesis of EV71
related severe diseases [13].
Antibody-dependent enhancement (ADE) of virus
infection is a phenomenon in which preexisting sub-
neutralizing antibodies enhance virus entry and replica-
tion. This phenomenon was first described by Hawkes
in 1964 [14], and then ADE infection has been identified
for many important viruses, including dengue virus,
respiratory syncytial virus, human immunodeficiency
virus, and Ebola virus. Several reports indicated that
ADE was observed for members of the Picornaviridae
family including foot-and-mouth disease virus [15],
poliovirus [16], and coxsackievirus B [17,18]. Just during
our submission, a group from Taiwan successfully
demonstrated the ADE infection of EV71 in THP-1 cells
for the first time [19].
Seroepidemiological survey has demonstrated that the
high morbidity and mortality occur in 6-11 months old
infants [20], which is correlated with the coincident
decline in maternal antibodies [21]. The association of
pre-existing antibodies with the increased severity of
disease deserves further concerns and investigation.
Here in this study, the possible role of sub-neutralizing
antibodies during EV71 infection in vitro and in vivo
was observed, and the association of ADE with disease
development was analyzed in a secondary EV71 infec-
tion model.
Results
P r e v i o u s l y ,w eh a v es h o wn that commercial human
IVIG preparations manufactured from Chinese plasma
donors contain high titer neutralizing antibodies against
EV71 [22]. Here to observe the possible ADE effects of
EV71 infection, varying concentrations of IVIG prepara-
tions were used to incubate with EV71 to form anti-
body-virus complex before infecting THP-1 cells. The
results of plaque assay showed that stock solution of
IVIG can completely block EV71 infection in THP-1
cells, and PBS control has no effects on viral yield as
expected (Figure 1A). Further dilutions of IVIG
decreased the ability of EV71 neutralization, while at the
10
-3 dilution of IVIG (50 μg/ml), a significant increase
in virus titer was observed. The curves of viral yield
from each dilutions coincided well with the ADE phe-
nomenon (Figure 1B). Furthermore, real-time RT-PCR
results also demonstrated that high concentration of
IVIG (10
-1 dilution) prevent EV71 infection, while lower
concentration of IVIG (10
-3 dilution) enhanced EV71
infection (data not shown). These experiments demon-
strated lower concentration of neutralizing antibodies
against EV71 can enhance EV71 infection in a monocy-
tic cell line.
Figure 1 ADE infection of EV71 in THP-1 cells mediated by
different concentrations of IVIG. Serial 10-fold IVIG dilutions were
pre-mixed with EV71 and then cultured in THP-1 cell for 24 h. (A)
Plaque forming assay of viral yield in THP-1 cells at 24 h post
infection. 10
0 dilutions of IVIG treatment completely block EV71
replication in THP-1 cells, an enhancement of viral yield was
observed at 10
-3 dilutions compared with the PBS control and 10
-2
or 10
-4 dilutions. (B) The dose range of enhancement of EV71
infection by IVIG. The error bars represent the standard deviations of
three independent experiments.
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tion in vivo, EV71 was pre-mixed with different con-
centration of IVIG or PBS were intraperitoneally
injected into 1-day-old mice (n = 11), respectively. The
survival curves (Figure 2A) showed that in the PBS
control group, 7 of 11 (64%) mice infected with EV71
infection survived. High concentration of IVIG (10
0
and 10
-1 dilutions) provided full protection against
lethal EV71 challenge, demonstrating the protective
role of neutralizing antibodies. Further dilution of
IVIG (10
-3 dilution) led to a similar effect as the PBS
control, indicating no effective neutralizing antibodies
at this concentration. Significantly, 10
-2 dilution of
IVIG (500 μg/ml) increased the mortality of EV71
infection, resulting in 80% deaths in EV71-infected
mice. These findings demonstrated that high concen-
tration of IVIG (10
0 and 10
-1 dilution) can prevent
deaths caused by EV71 infection in mice, while the
pre-incubation of EV71 with sub-neutralization con-
centration of IVIG (10
-2 dilution) increased the mortal-
ity of EV71 infection in mice, thus ADE phenomenon
occurred in vivo (Figure 2B).
Secondary infection model of dengue virus had been
well established for ADE research in mice [23] and
Rhesus monkeys [24]. Here, we manage to develop a
secondary infection model of EV71 in which 1-day-old
mice were first infected with an avirulent EV71 strain
HN08/08 and subsequently infected with a virulent
EV71 strain AH08/06 14 days after the primary infec-
tion. After the primary infection with HN08/08, all the
infected mice survived, and no neurological symptoms
developed. Serum examination showed that no neutra-
lizing antibodies (< 1:8) were detected in all of the
infected mice, that means only sub-neutralizing anti-
body was induced. While after the secondary infection
with the virulent strain AH08/06, groups of mice that
primary injected with HN08/08 developed typical neu-
rological manifestation, including movement disorien-
tation, hind limb paralysis and opisthotonus (Figure 3).
The survival curves (Figure 4) showed that 44% (4 of 9)
of the mice that primary injected with PBS survived
after the secondary infection with AH08/06. While
primary injected with 10
5 and 10
6 PFU of HN08/08
significantly increased the mortality to 100%, and all of
the mice died within 9-14 days after the secondary
infection. Additionally, primary injected with a higher
dose (10
7 PFU) of HN08/08 resulted in 50% (5 of 10)
deaths, conferring no significant difference with the
PBS control group. Thus, previous infection with
10
5 and 10
6 PFU EV71 was shown to increase the
mortality of sequential EV71 infection in mice.
Together, these results strongly indicated that the pre-
infection induced sub-neutralizing antibodies might
enhance EV71 infection, and might be associated with
disease development.
Figure 2 Lower concentration of IVIG enhanced the mortality
of EV71-infected mice. Groups of 1-day-old mice (n = 11) were
injected with 1 LD50 of AH08/06 strain pre-mixed with varying
concentration of IVIG. The mortality was further monitored for
2 weeks. (A) Kaplan-Meier survival curves were analyzed by the
log-rank test and compared to curves of the PBS controls.
Significant differences are indicated by asterisks. (B) Mortality curves
of mice treated with different IVIG dilutions. 10
-2 dilution of IVIG
resulted in 80% death in EV71-infected mice.
Figure 3 A representative picture of hind limb paralysis caused
by the secondary infection of EV71 (10 days post the
secondary infection). The mouse on the right-hand side is an age-
matched (23-day-old) control.
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Our results provided evidence that pre-existing antibodies
can enhance EV71 infection in vitro and in vivo. High con-
centration of IVIG can neutralize EV71, while further dilu-
tions of IVIG led to an increase of viral replication and
yield in THP-1 cells, and resulted in a higher mortality in
mice. In the secondary EV71 infection model, primary
infection with an avirulent EV71 strain result in a higher
mortality of sequential EV71 infection in mice, indicating
previous EV71 infection may be a potential risk factor for
severe diseases during sequential EV71 infection. The pre-
sent findings not only indicate ADE contribute to the
pathogenesis of severe EV71 infection, but also raise prac-
tical issues about the development of vaccines and passive
therapy with antibodies against EV71.
Mouse and cynomolgus macaque models have been
established to study the pathogenesis and evaluate anti-
virals and vaccines [25]. Experimental infection with
EV71 has been shown to cause death in neonatal mice
in an age- and dose-dependent manner [26]. And 14-
day-old suckling mice are susceptible to virulent EV71
strain and have been used for vaccine evaluation [27].
The virulent strain AH08/06 and avirulent strain HN08/
08 were both isolated in our laboratory and intraperito-
neally injection with AH08/06 can result in neurological
symptoms and deaths in different age of suckling mice
[28]. EV71 antigen can be detected in the brain, and his-
topathological analysis of tissues from mice showed
signs of infection (unpublished data). By using these
strains, the secondary EV71 infection model were devel-
oped, and the results showed that preliminary exposure
to an avirulent EV71 strain before secondary EV71
infection increased the risk of developing severe neuro-
logical complications and deaths. Multiple genotypes of
EV71 strains co-circulate in in the same areas for a long
time [10], and large outbreaks are probably associated
with genotype replacement [8]. A recent report has
shown that repeated EV71 infection is common during
large outbreaks in China [29]. This is particularly impor-
tant considering the fact that most primary EV71 infec-
tions are asymptomatic.
The target cells of EV71 in human tissues and organs
have not been identified. Previous experiments showed
that coxsackieviruses could replicate in lymphocytes and
monocytes [17,30]. Human monocytic cell line THP-1
has Fc and complement receptor that is used for in
vitro ADE assay in this study. The mechanism for ADE
of EV71 infection is still unknown. Different mechan-
isms for ADE has been hypothesized, in which Fc recep-
tor, complement receptor, b2-microglobulin have been
reported to play a role. Wang et al recently demon-
strated that Fcg-receptor may participate in EV71-
induced ADE based on results from THP-1 cells [19].
Arita et al also reported high-affinity Fc receptor
mediated enhancement of poliovirus infection [31].
Further, EV71 encodes 4 structural proteins (VP1-4),
and the viral antigenic determinants associated with
ADE of EV71 are also critical for future investigation.
Recently, Chehadeh et al. [32] demonstrated that VP4
protein is the major target of enhancing antibodies in
the CVB4 and CVB3 ADE model. By using monoclonal
antibodies screening, the prM protein of dengue virus
was recently identified as the critical ADE determinants
[33]. We have produced a panel of EV71 mAbs and
such efforts are currently underway. Additionally, ADE
infection of non-enveloped virus requires binding of
virus-antibody complexes both to Fcg-receptor and to
the specific viral receptor [34]. The role of PSGL-1 [35]
and SCARB2 [36], two EV71 receptors, during ADE of
EV71 infection deserves further research.
IVIG is a pharmaceutically preparation of human IgG
that has immunoregulatory and anti-inflammatory proper-
ties. Clinically administration during EV71 outbreaks in
Taiwan [37,38] had achieved an improvement in clinical
outcome. The Ministry of Health of China has recom-
mended high dose (total 2 g/kg in 2-5 days) of IVIG for
treatment of severe EV71 infection. However, considering
the fact that IVIG contains anti-EV71 antibodies [22], the
potential risk of IVIG induced ADE of EV71 infection,
especially the dose, must be carefully considered in future
clinical application. The enhancing concentrations of IVIG
may vary. Our experiments showed 50 μg/ml of IVIG
enhanced EV71 infection in vitro, while 500 μg/ml in vivo.
Figure 4 The secondary infection model of EV71.G r o u p so f1 -
day-old mice were first injected with different doses (10
5,1 0
6, and
10
7 PFU/per mouse) of an avirulent EV71 strain (HN08/08) and then
challenged with a virulent EV71 strain (AH08/06) 14 days later. The
surviving curves after the secondary EV71 infection was analyzed by
log-rank test and significant differences are indicated by asterisks.
One representation of three independent experiments is shown.
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enhanced EV71 infection in THP-1 cells. The difference
may results from the different sources of IVIG and the
methodology applied [19,22].
Given the public health significance of EV71, a wide
range of experimental EV71 vaccine approaches have
been studied, and neutralizing antibodies have been sug-
gested as one of the most important factors in limiting
the severity of infection. But considering the possible
impact of ADE, vaccines should be carefully designed to
avoid the induction of known enhancing antibodies.
Antibody responses induced by inactivated or subunit
vaccines tend to be associated with severe disease by
respiratory syncytial virus and retroviruses [39,40].
Induction of cellular immunity, rather than antibodies,
may represent an alternative strategy for future EV71
vaccine development [41]. Live attenuated vaccine other
than inactivated vaccine will be a good candidate.
Taken together, the present findings from laboratory
and animal experiments demonstrate that the presence
of sub-neutralizing antibodies would enhance EV71
infection, and primary EV71 infection might represent a
risk factor of severe diseases during sequential EV71
infection. Controlled clinical trials are critically needed
to confirm the correlation between disease severity and
ADE. Also, much effort is currently underway to deter-
mine the cellular and viral determinants of EV71-
induced ADE. The results of this and future studies thus
contribute to a better understanding of the pathogenesis
of EV71 infection, as well as an improved ability to eval-
uate vaccines and therapeutic antibodies.
Materials and methods
Viruses and cells
Human rhabdomyosarcoma (RD) cells were cultured
with DMEM supplemented with 2% fetal bovine serum
(FBS), 100 IU of penicillin, and 100 μg of streptomycin
per ml at 37°C in the presence of 5% CO2. Human mono-
cytic cells (THP-1) were used for in vitro ADE assay and
maintained in RPMI-1640 media at 37°C in 5% CO2.
EV71 strain AH08/06 was isolated from the throat swab
sample of an HFMD case during an outbreak in 2008 in
Anhui, China [39]. EV71 strain HN08/08 was isolated
from the stool sample of an HFMD case during an out-
break in 2008 in Henan, China. All the viruses were pro-
pagated and titrated in RD cells and the stock was stored
in aliquots at -80°C in our laboratory. The titer of EV71
was expressed as 50% tissue culture infection dose
(TCID50), plaque-forming units (PFU) or 50% lethal dose
(LD50) according to the Reed-Muench method [42].
Microneutralizing assay
The titer of neutralizing antibodies against EV71 was
determined in RD cells according to standard protocol
[ 4 3 ] .B r i e f l y ,5 0μL of sample dilutions and 50 μLo f
virus stock containing 100 TCID50 EV71 were mixed
and incubated onto the microtiter plates with RD cells
at 37°C for 6 days. All the samples were tested at an
initial dilution of 1: 8, and cell and virus controls were
run simultaneously. The neutralizing antibody titer was
defined as the highest dilution of serum that could pre-
vent the occurrence of cytopathic effect.
Human Intravenous Immunoglobulin (IVIG) preparations
Human 5% liquid IVIG preparations (5 g/100 ml, Ton-
rol Bio-Pharmaceutical) manufactured from Chinese
plasma donors, consisting more than 99% of IgG and a
very small quantities of IgA and IgM, were used as
stock dilutions. The titer of neutralizing antibodies of
IVIG was calculated to 1:128 by microneutralzing assay
as previously described.
ADE infection assay in vitro
Stock IVIG preparation (10
0 dilution) was 10-fold serially
diluted to 10
-4 with PBS and each dilution was then incu-
bated with EV71 suspensions at 37°C for 1 h to form
virus-antibody complexes, respectively. The EV71-anti-
body complexes were then added to cultured THP-1 cells
at a multiplicity of infection (MOI) of 1 and incubated for
1 h at 37°C. Then, THP-1 cells were washed for three
times with PBS and then incubated with fresh RPMI-1640
media for another 24 h. Finally, the infected cells and
supernatants were harvested and the virus yield was deter-
mined by the plaque assays and real-time RT-PCR assays.
Plaque forming assay
Monolayer RD cells were cultured in 12-well plates and
serial 10-fold dilutions of viral suspensions were added
for adsorption for 1 h. Then, the virus suspension was
replaced with DMEM containing 2% FBS and low melt-
ing point agarose. Followed by incubation for 72 h, the
cells were fixed with 10% formaldehyde and subse-
quently stained with 1% crystal violet solution. The titer
of EV71 was calculated and expressed as plaque-forming
units (PFU)/ml.
Real-time RT-PCR assay
Viral RNA in EV71-infected THP-1 cells was assayed by
real-time RT-PCR as previously described [44]. Viral
RNA was extracted by the QIAmp Viral RNA Mini kit
(Qiagen) and one-step RT-PCR was performed by using
the PrimeScript One-Step RT-PCR kit (Takara) accord-
ing to the manufacturer’s instructions in Roche LightCy-
cler 2.0 systems.
In vivo neutralization assay of EV71
Stock IVIG preparation was 10-fold serially diluted
mixed with EV71 suspensions as previous described.
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injected intraperitoneally with these EV71-IVIG or
EV71-PBS mixtures, respectively. The mortality and
neurological symptoms were monitored for 15 days.
Secondary EV71 infection model
We use two EV71 strains to establish the secondary
EV71 infection model: a virulent strain AH08/06 which
can result in death in 14-day-old suckling mice and an
avirulent strain HN08/08. Briefly, groups of suckling
mice of 1-day-old were primary injected subcutaneously
with 50 μlo fd i f f e r e n td o s e s( 1 0
5,1 0
6 and 10
7 PFU,
respectively) of HN08/08 or PBS. Then 14 days after the
p r i m a r yi n f e c t i o n ,a l lt h em i c ew e r es u b s e q u e n t l y
infected with 1 LD50 (50 μl) of AH08/06 by intraperito-
neally injection. Before the secondary infection, 100 μl
of blood was obtained via tail vein bleeding and pro-
cessed for microneutralizing assay. The mortality and
neurological symptoms were followed for another
14 days post the secondary infection. All the animal
experiments were approved and performed according to
the guideline of Animal Experiment Committee of State
Key Laboratory of Pathogen and Biosecurity.
Statistical analysis
Kaplan-Meier survival curves were used to display mor-
tality data, and log rank analyses were performed to
determine statistical significance between different
groups.
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